Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-H vs P-H in Low-Risk HER2+ Breast Cancer
NCT03705429Phase 3Completed
- Start
- May 2019
- Primary completion
- May 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, cyclophosphamide, paclitaxel and trastuzumab in HER2-positive breast cancer (2 arms). Primary endpoint: Feasibility of performing a pragmatic clinical trial with an Integrated Consent Model at 12 months. Started May 2019; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03705429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03705429.